KRT6A Recombinant Monoclonal Antibody

Code CSB-RA788545A0HU
Size US$210
Order now
Image
  • Immunofluorescence staining of A549 with CSB-RA788545A0HU at 1:10, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 519-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
  • Overlay Peak curve showing Hela cells stained with CSB-RA788545A0HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
KRT6A
Alternative Names
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Cytokeratin-6D) (CK-6D) (Keratin-6A) (K6A) (Type-II keratin Kb6) (allergen Hom s 5), KRT6A, K6A KRT6D
Species Reactivity
Human
Immunogen
A synthesized peptide derived from Human KRT6A
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
21E2
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, IF, FC
Recommended Dilution
Application Recommended Dilution
IF 1:50-1:200
FC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

Employing in vitro expression systems, the KRT6A recombinant monoclonal antibody is synthesized by cloning DNA sequences of KRT6A antibodies sourced from immunoreactive rabbits. The immunogen utilized is a synthesized peptide derived from the human KRT6A protein. Subsequently, the genes coding for the KRT6A antibodies are inserted into plasmid vectors, and these recombinant plasmid vectors are then transfected into host cells to enable the expression of the antibody. Following expression, the KRT6A recombinant monoclonal antibody undergoes affinity-chromatography purification and is rigorously tested for functionality in ELISA, IF, and FC applications, confirming reactivity with the human KRT6A protein.

KRT6A is a keratin protein that primarily provides structural support to epithelial tissues, including the skin, hair, and nails. Its functions are essential for maintaining the structural integrity of these tissues and for protecting the body from external factors. Dysregulation of KRT6A and other keratins can lead to various skin and nail disorders.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair.
Gene References into Functions
  1. Manipulating K6a phosphorylation or ubiquitin-proteasome system (UPS) activity may provide opportunities to harness the innate immunity of epithelia against infection. PMID: 29191848
  2. Several missense polymorphisms in KRT6A, KRT6B and KRT6C that lead to a higher risk for dental caries. PMID: 29357356
  3. KRT6A genetic mutation is associate with the development of Pachyonychia Congenita in patients in Australia. PMID: 27041546
  4. we here describe a family with pachyonychia congenita K6a, manifesting atypical symptoms of impaired wound healing and cheilitis. PMID: 24708461
  5. Keratin-derived antimicrobial peptides (KDAMPs) and their synthetic analogs exhibit antimicrobial activity against bacterial pathogens. PMID: 23006328
  6. Genotype-phenotype correlations among PC patients with codon-125 mutation in KRT16 were established, while the phenotypes caused by the IVS8-2A>C mutation in KRT6A need further studies to confirm the rare feature of fissured tongue PMID: 22668561
  7. We observed a higher likelihood of oral leukokeratosis in individuals harboring KRT6A mutations. PMID: 22264670
  8. Phenotypic differences exist between KRT6A and KRT16 mutations support adoption of a new classification system. PMID: 22098151
  9. This report is the first case of pachyonychia congenita with laryngeal obstruction in which the gene mutation has been established (a deletional mutation in keratin 6a). PMID: 21554383
  10. Focal palmoplantar keratoderma is associated with mutations in keratin K6c in 3 families. 2 unrelated families have Asn172 del and the other has a deletion of AA 462-470. Review. PMID: 20470930
  11. these data highlight the possibility of a physiological role for K6/K16 heterodimers in keratinocyte cell migration, in addition to the heterodimer's known functions in cell differentiation and mechanical resilience. PMID: 20403371
  12. The mutation of 521T--> C in the K6A gene is the causing mutation in pachyonychia congenita type I. PMID: 20140871
  13. Mutations Y465H and N171D of the KRT16A gene were detected in the sporadic pachyonychia congenita cases. PMID: 19806570
  14. Four new missense and five known mutations in K6a, one new deletion and three previously identified missense mutations in K16, plus one known mutation in K17 are reported in pachyonychia congenita. PMID: 17719747
  15. PC-1 is due to mutations of the KRT16 gene or its expression partner KRT6A, wheres PC-2 is caused by mutations in the KRT17 or KRT6B genes. PMID: 18489596
  16. Three novel and four recurrent keratin 6A (KRT6A) mutations were found in Chinese patients with pachyonychia congenita type 1 PMID: 19416275
  17. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. PMID: 19699613

Show More

Hide All

Involvement in disease
Pachyonychia congenita 3 (PC3)
Protein Families
Intermediate filament family
Tissue Specificity
Expressed in the corneal epithelium (at protein level).
Database Links

HGNC: 6443

OMIM: 148041

KEGG: hsa:3853

STRING: 9606.ENSP00000369317

UniGene: Hs.700779

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*